Zobrazeno 1 - 3
of 3
pro vyhledávání: '"J. Z. Zack"'
Publikováno v:
Clinical Pharmacology & Therapeutics. 79:P4-P4
BACKGROUND To predict the activity of various LZD dosage regimens for MRSA. The MIC90 of LZD against MRSA is ∼4 mg/L. METHODS For 2 clinical MRSA isolates (MIC2, MIC4), 24h kill curve experiments were fit by a PD model: capacity limited replication
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::125d3d0717dcedd583285aa62bc1324a
https://doi.org/10.1016/j.clpt.2005.12.012
https://doi.org/10.1016/j.clpt.2005.12.012
Autor:
J. Z. Zack, Gene D. Morse, O. O. Okusanya, A. Forrest, E. Adams, Richard C. Reichman, S. Rosenkranz, K. Yaresheski, M. F. Para
Publikováno v:
Clinical Pharmacology & Therapeutics. 77:P79-P79
Aims SQV is a PI used, in combinations, in patients with HIV. Because compartmental PK analyses are unavailable, to date, our aim is to develop & report a valid PK model & parameters for SQV. Methods Ten healthy HIV seronegative subjects were adminis
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b1ad29d4addefd3e6dfbb613e74ee5aa
https://doi.org/10.1016/j.clpt.2004.12.195
https://doi.org/10.1016/j.clpt.2004.12.195
Autor:
A. Forrest, Gene D. Morse, Qing Ma, S. Rosenkranz, E. Adams, J. Z. Zack, Richard C. Reichman, K. Yaresheski, M. F. Para
Publikováno v:
Clinical Pharmacology & Therapeutics. 77:P90-P90
Aims ARV therapy is a rapidly evolving area that requires an excellent understanding of drug interactions & metabolism as well as adaptive feedback control (PK/PD individualization). Clinicians & patients are confronted with increasingly complex regi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::34a64d3939d1b0aa9e2383f4558c0911
https://doi.org/10.1016/j.clpt.2004.12.236
https://doi.org/10.1016/j.clpt.2004.12.236